

Michael L Maitland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3581453/publications.pdf>

Version: 2024-02-01

36
papers

2,027
citations

430874

18
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

3158
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. <i>Journal of the American College of Cardiology</i> , 2009, 54, S10-S19.	2.8	605
2	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. <i>Journal of the National Cancer Institute</i> , 2010, 102, 596-604.	6.3	381
3	Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1455-1461.	6.3	156
4	Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment. <i>Clinical Cancer Research</i> , 2009, 15, 6250-6257.	7.0	156
5	TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 432-437.	8.7	87
6	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point. <i>Cancer Research</i> , 2012, 72, 5145-5149.	0.9	77
7	Clinical trials in the era of personalized oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 365-381.	329.8	56
8	Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology. <i>Clinical Cancer Research</i> , 2010, 16, 5296-5302.	7.0	46
9	Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics. <i>Journal of Clinical Oncology</i> , 2006, 24, 2151-2157.	1.6	44
10	Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets. <i>Annals of Internal Medicine</i> , 2006, 145, 702.	3.9	39
11	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4511-4520.	7.0	39
12	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. <i>Cancer Research</i> , 2016, 76, 117-126.	0.9	36
13	Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients. <i>Clinical Cancer Research</i> , 2013, 19, 3059-3067.	7.0	33
14	Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. <i>Journal of Biomedical Informatics</i> , 2010, 43, 376-384.	4.3	32
15	Identification of a Variant in <i>KDR</i> Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib. <i>Clinical Cancer Research</i> , 2015, 21, 365-372.	7.0	29
16	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2018, 118, 1042-1050.	6.4	27
17	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 298-306.	2.6	26
18	Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 29-36.	2.3	24

#	ARTICLE	IF	CITATIONS
19	Vascular endothelial growth factor pathway. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 346-349.	1.5	18
20	Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv247.	6.3	18
21	PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5565-5565.	1.6	18
22	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. <i>Clinical Cancer Research</i> , 2020, 26, 6464-6474.	7.0	16
23	Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 243-245.	2.0	15
24	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	2.1	14
25	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 309-317.	2.3	12
26	Get Real: Integration of Real-World Data to Improve Patient Care. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 722-725.	4.7	6
27	Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 5.	2.6	3
28	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. <i>Clinical Cancer Research</i> , 2015, 21, 5092-5099.	7.0	3
29	Cancer Clinical Investigators Should Converge with Pharmacometricians. <i>Clinical Cancer Research</i> , 2019, 25, 5182-5184.	7.0	3
30	More Sound Cancer Therapy Biomarker Development With Active Noise Control. <i>Oncologist</i> , 2013, 18, 239-241.	3.7	2
31	Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2574-2574.	1.6	2
32	Cardiovascular toxicity of new agents. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 657-9.	0.3	2
33	Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 986-997.	6.9	1
34	Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. <i>Pharmacogenetics and Genomics</i> , 2022, Publish Ahead of Print, .	1.5	1
35	Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer. <i>Gynecologic Oncology</i> , 2021, 160, 295-301.	1.4	0
36	Advances in biomarkers for targeted agents. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 688-90.	0.3	0